staining was done to detect the presence of acid fast
bacilii that could cause cutaneous tuberculosis or
infections of atypical Mycobacteria.
Polymerase chain reaction (PCR) examination
can detect the tuberculosis and nontuberculosbacteria
DNA from skin tissue. In this case report, the patient
first complained of painless nodules in the left arm,
left elbow, right hip, and buttocks since two months
before consultation. The nodules were getting bigger
and multiplied in the month before consultation and
the nodules on the left buttock became ulcers. There
was edema and indurations around the nodules. There
was no hystory of lymphadenitis or grain in the fluid
from the ulcer, no fungal growth in the fungal
cultures, no acid fast bacteria from the Ziehl-Neelsen
staining, and the results from the PCR was negative.
The results from the bacterial culture was anaerobic
bacteria (Propionibcaterium propionicum).
Histopathology examination showed hyalinisation of
the fibrocollageneous tissue with inflammation cells
(lymphocytes, histiocytes, eosinofil, and
polymorphonuclear cells), there were lymphocytes on
the perivascular tissue, no spores, no hyphae, and no
epitelioid datia Langhans cells or caseous necrosis.
The treatment of actinomycetoma could be done
with antimicrobial agents and surgery. Amputation as
a single therapy rarely gives good results. Surgery can
remove small lesions or reduce the size of the lesion.
The recommendations of drug regimens are based on
expert experience. There are no randomized
controlled trials for effective therapy regimens for
mycetoma. The treatment is given in combination
regimens to prevent drug resistance. The duration of
therapy is 3-24 months depending on the response of
the patient. The healing of the lesions can be assessed
based on subcutaneous nodules and sinus, or
indurations of the skin. Various antibiotic therapies
for actinomycetoma are aminoglycosides (amikacin
or netilmicin), rifampicin, amoxicillin-clavulanic
acid, fusidic acid, clindamycin, imipenem-silastin,
(Hay, 2012) moxifloxacin, or the tetracycline group
(oxytetracycline, minoxycline, or doxycycline)
(Bravo et al., 2012).
There is a case reporting actinomycetoma in a 32-
year-old woman treated with benzylpenicillin
8,000,000 IU injections four times daily and
cotrimoxazole tablet twice daily for twenty days,
followed by twice daily cotrimoxazole and 500 mg
amoxicillin four times daily. Two months after the
therapy there was significant improvement of sinus
fibrosis, no induration, no secretions, no new lesions,
and no systemic symptoms. The mechanism of action
of beta lactam antibiotics is bactericidal by binding to
specific proteins of penicillin-binding, inhibit
peptidoglycan synthesis and inhibit the autolithic
enzymes of bacterial cell walls. Clavulanic acid
obtained from isolated metabolite Streptomyces
clavuligerus,
11
can inhibit beta lactamase.
11
Amoxicillin-clavulanic acid has a major influence for
Gram positive and Gram negative bacteria.
11
In this
case the patients was given amoxicillin clavulanic
acid based on the results of antibiotic susceptibility
test against Propionibacterium propionicum and the
recommended therapy for actinomycetoma.
4 CONCLUSION
Our case demonstrates actinomycetoma with oral
amoxicillin clavulanic acid for therapy. Actinomyces
sp. can cause actinomycetoma. Propionibacterium
propionicum or known as Actinomyces meyeri is a
form of bacteria incorporated in the species
Actinomyces microorganisms cause actinomycetoma
(Bravo et al., 2012). Various regimens of antibiotics
can be given for actinomycetoma, such as
aminoglycoside group, rifampicin, amoxicillin-
clavulanic acid, fusidic acid, clindamycin, imipenem-
silastin, moxifloxacin, or tetracycline group
(oxytetracycline, minoxycline, or doxycycline).
Amoxicillin is often combined with clavulanic acid
which has a major effect on disease therapy infections
caused by Gram positive and Gram negative bacteria.
In this case patients are given amoxicillin clavulanic
acid therapy in accordance with the results of
antibiotic susceptibility test against
Propionibacterium propionicum and recommended
therapy for actinomycetoma.
REFERENCES
Branscomb, R., 2003. Mycetoma: an overview. Laboratory
Medicine. 11, pp. 803-808.
Bravo, F.G., Arenas, R., Sigall, D.A. 2012. Actinomycosis,
nocardiosis, and actinomycetoma. In: Goldsmith LA,
Katz SI, Gilchrest BA, Paller AS, Leffel DA, Wolff K,
editor. Fitzpatrick’s dermatology in general medicine.
8
th
edition. New York: McGraw-Hill. Page:2241-52.
Chávez, G., Estrada, R., Bonifaz, A., 2002. Perianal
actinomycetoma experience of 20 cases, in:
International Journal of Dermatology. pp. 491–493.
doi:10.1046/j.1365-4362.2002.01550.x
Executive Board. Mycetoma., 2015. World Health
Organization (WHO).
Gomez, A., Saul, A., Bonifaz, A., Lopez, M. 1993.
Amoxicillin and Clavulanic Acid in The Treatment Of
Actinomycetoma. International Journal of